SAE Media Group will host an AI drug discovery conference in London on 13‑14 March 2023, aiming to showcase how machine‑learning tools can cut the time and cost of new medicines.
Automation and digital twins take center stage
The two‑day gathering at the Copthorne Tara Hotel will feature sessions on robotics, quantum chemistry and the use of digital twins to model molecular behavior. Organisers say the agenda reflects growing pressure to speed up pipelines that traditionally span years and billions of dollars.
Speakers from major firms such as GSK, Bayer and Janssen Pharmaceuticals will describe recent projects that combine structure‑based target selection with in‑silico simulations. Attendees can expect case studies on knowledge graphs and molecular trends that illustrate how data‑rich models inform lead optimization.
One panel will explore how open‑source data and international cooperation helped accelerate Covid‑19 therapeutic development. Participants will discuss whether those collaborative practices can become a standard part of future R&D workflows.
Industry leaders share latest research
Beyond technical talks, the event will address patient‑centric precision medicine. A session on fragment‑based selection promises to explain how smaller molecular pieces can be stitched together to target previously “undruggable” proteins.
Related: AI finds antibiotic candidates in prion proteins
Another discussion will focus on the integration of AI across the discovery pipeline, from antigen identification to peptide design.
Registrations are being accepted through the official site. Interested professionals can sign up at the conference portal. Organisers expect several thousand senior scientists and executives to attend, creating networking opportunities that span both academia and industry.
SAE Media Group, a subsidiary of SAE International, runs more than 60 high‑level events worldwide, covering sectors from aerospace to medical technology. Its London‑based conference arm typically draws over 5,000 senior business professionals each year.
According to the company, the AI drug discovery event is part of a broader strategy to connect global communities with focused networking opportunities. The aim is to equip participants with actionable insights that can be applied directly to their organisations’ R&D challenges.
